Inflection Strategy helps biotech companies approaching Phase 2 readouts, Phase 3 readouts, PDUFA dates, and commercial launches identify and resolve organizational gaps before they compound into failure.
Where execution fails, talent was load-bearing.
These are not hypothetical risks. They are the documented failure patterns of late-stage biotech companies that had the science — and lost the inflection. The ISF is calibrated to find them before they cost you the readout, the approval, or the launch.
The CEO, CMO, and CCO describe different priorities and decision criteria when interviewed separately. No one on the team knows this — until the moment of maximum external pressure.
The board has not reviewed or pre-authorized contingency plans for the most likely adverse outcome. When the readout comes, the organization spends the first 72 hours seeking alignment that should have been pre-built.
No single executive owns the FDA response protocol. Accountability is shared across regulatory, legal, and medical — which means when an unexpected data query arrives, the response fragments along functional lines.
Regulatory and commercial planning are running on separate timelines with separate assumptions. Neither team knows the other's critical path. The failure will happen at the interface, not inside either function.
Market access and HEOR were not involved in clinical data architecture decisions. Post-approval, the commercial analytics team inherits a dataset designed for endpoint validation — not payer segmentation or outcomes evidence.
The investor communication sequence for the PDUFA decision has not been rehearsed. IR, legal, and the CEO have not pre-aligned on disclosure triggers. Conflicting signals reach institutional holders within hours of the decision.
The Inflection Strategy Framework is a structured diagnostic system — organizational domains, a pattern library of documented failure modes, and real-time signal detection. It is not a consulting template. It is a methodology for seeing what is missing when the clock is running, and quantifying the risk before it surfaces publicly. The architecture spans 27 domains, 85 sub-domains, and 374 diagnostic questions.
Domain scoring is not a grade — it is an operational directive. Each signal level tells your leadership team what to do, not just what was found. The output is a written engagement report built for the CEO and board, not a consulting artifact.
One or more red-flag thresholds crossed. Represents a material execution risk likely to manifest at the inflection event. Requires executive-level intervention and a named remediation owner within 30 days.
Conditions present that could escalate under pressure. No red flags crossed, but incomplete governance or cross-functional alignment creates latent risk. Requires named owners and 30-day checkpoint cadence.
Domain governance is in place, documented, and stress-tested within the past quarter. Confirmation that this domain will not be a constraint at the inflection event. No further action required at this time.
Structured signal capture, domain scoring, seam analysis, and executive recommendation generation. The ISF operates through a purpose-built session instrument — capturing signals, scoring domains, assessing seam vulnerabilities, and generating a structured report in real time, during the executive interview itself.
V2.0 · 27 Domains · 374 Questions · Session Persistence · PDF Export
Signal capture → Domain diagnosis → Seam-risk mapping → Executive recommendation
Illustrative example — anonymized late-stage biotechnology company approaching commercialization
A Claude-enabled ISF diagnostic identified elevated organizational execution risk despite positive clinical momentum and a credible path toward commercialization.
No individual finding independently suggested execution failure. Risk emerged through interaction effects — leadership transition, commercialization readiness gaps, and cross-functional coordination pressure combined to elevate execution vulnerability ahead of a critical business inflection.
Conduct milestone-anchored readiness reviews, clarify executive operating governance, and sequence commercialization capabilities 12–18 months ahead of the anticipated inflection event to reduce execution compression risk.
Strategy consultants, M&A advisors, and investment firms conducting pre-deal or portfolio operational reviews can license the ISF Diagnostic Workbench as a standalone diagnostic instrument — deploying it across client engagements under a structured annual license. The Workbench provides the session capture, signal scoring, and report generation infrastructure. The ISF methodology provides the diagnostic architecture.
Late-stage biotechs and commercial-stage pharma companies can license the ISF Diagnostic Workbench enterprise-wide — giving CEOs, COOs, CCOs, and CFOs a shared diagnostic architecture for tracking readiness across all 27 domains. Run it as a pre-inflection operational audit, a quarterly cross-functional alignment tool, or standing board and investor prep. The Workbench captures the signal. Your leadership team acts on it.
Engagements are structured around your inflection timeline. We identify the risk, quantify it, and when needed, help you act on it — through our integrated advisory and executive search capabilities.
A structured ISF assessment across all 27 domains, delivered as a scored gap analysis with prioritized risk recommendations. The foundation of every engagement.
Step 0 CalibrationEmbedded advisory support as you navigate pre-launch execution. Scenario planning, cross-functional coordination, and executive counsel during the critical 12–24 month window.
Ongoing EngagementWhen the diagnostic reveals human capital gaps, our executive search practice — operating as the talent arm of Inflection Strategy — helps source and place the senior commercial, medical, and market access leaders you need.
Recruit LS DivisionI have spent 25 years at the intersection of strategy, talent, and commercial execution in life sciences — as a business development advisor at Oracle Life Sciences and Cap Gemini, as a senior executive recruiter across pharma and biotech, and as an angel investor and CEO coach.
That vantage point — across dozens of organizations at their most pressured moments — is where the Inflection Strategy Framework was born. I have seen the same execution failures repeat across organizations of different sizes and therapeutic areas. They are not random. They are diagnosable.
My work is not turnaround consulting. It is pre-crisis diagnostic work — for organizations that are fundamentally sound but need a structured way to see their own blind spots before the clock runs out. The ISF is that structure.
When the diagnostic reveals a gap, I help think through how to close it — whether through advisory support, executive search, or, when the situation calls for it, working in an embedded capacity alongside the leadership team.
Companies 12–24 months from a PDUFA date or commercial launch that need a structured view of organizational readiness before the pressure peaks.
Senior executives who sense organizational gaps across functions but lack an independent diagnostic framework to surface, map, and prioritize them.
Investment partners and board members stress-testing pre-launch execution readiness — seeking an outside view before a critical binary event.
Whether you're approaching a critical inflection, exploring the framework, or simply want to talk through an organizational challenge — reach out. Larry responds to every inquiry personally.